Latest Articles
Episode 2: Quality of Life and Endometrial Cancer Survivorship - Medscape
Episode 2: Quality of Life and Endometrial Cancer Survivorship Medscape
Published: June 25, 2024, 7 a.m.
Endometrial cancer | Healthwatch 16 - WNEP Scranton/Wilkes-Barre
Endometrial cancer | Healthwatch 16 WNEP Scranton/Wilkes-Barre
Published: June 25, 2024, 7 a.m.
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma - OncLive
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma OncLive
Published: June 20, 2024, 7 a.m.
Novotech Publishes Report on Research into Endometrial - GlobeNewswire
Novotech Publishes Report on Research into Endometrial GlobeNewswire
Published: June 20, 2024, 7 a.m.
IVF live birth rate lower with deep infiltrating endometriosis, endometrioma - Healio
IVF live birth rate lower with deep infiltrating endometriosis, endometrioma Healio
Published: June 19, 2024, 7 a.m.
The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile - Wiley Online Library
The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile Wiley Online Library
Published: June 18, 2024, 7 a.m.
This Tucson woman doesn’t trust the AZ GOP to protect access to contraceptives - The Copper Courier
This Tucson woman doesn’t trust the AZ GOP to protect access to contraceptives The Copper Courier
Published: June 18, 2024, 7 a.m.
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval - FiercePharma
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval FiercePharma
Published: June 18, 2024, 7 a.m.
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? - FiercePharma
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? FiercePharma
Published: June 17, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Link copied to clipboard!